Merck Announces Third-quarter 2022 Monetary Outcomes
As Rob noted, we see considerable opportunity to make an impact in cardiovascular illness. It is my pleasure to supply an update on our progress because the second quarter call. We have developing momentum in our pipeline across therapeutic places, across modalities, across stages of improvement and across the spectrum of internal applications, established partnerships, and recent business improvement possibilities. In cardiology, we are making strong headway in pulmonary arterial hypertension as well as our PCSK9 and Issue XI program….